Department of aGastroenterology, Hopital Cochin, Paris, France.
Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1281-7. doi: 10.1097/MEG.0b013e328357cdfd.
Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) can be coupled with endoscopic retrograde cholangiopancreatography in the same setting when biliary and/or duodenal stenting are required.
Our aim was to examine the effectiveness of EUS-FNA combined with stenting during the same session in patients with pancreatic cancer.
Consecutive patients referred for EUS-FNA of a pancreatic mass with symptoms of biliary (±upper digestive) obstruction were included. Consecutive patients undergoing biliary and/or duodenal stenting without EUS-FNA during the same period were used as controls. Procedure-related complications were the primary outcome measure. Duration of the procedure, ability to achieve biliary/duodenal stenting, the yield of EUS-FNA, and clinical outcomes were evaluated.
A total of 122 patients underwent combined EUS-FNA and stenting and 68 underwent stenting alone (control group). In the combined group, histological proof of cancer was obtained in 88.52% at first EUS-FNA and 95.08% after a second EUS-FNA. Biliary stent placement was successful in 97.5 and 98% in the combined and the control groups, respectively. There was no statistical difference between the groups for length of stay after endoscopy and for procedure-related mortality and morbidity within 30 days. The median time from endoscopy to chemotherapy in the combined group was 12 days.
Combined EUS-FNA and biliary and/or duodenal stenting is feasible in almost all patients with suspected pancreatic cancer, with no additional hazard and a high histological yield.
当需要胆道和/或十二指肠支架置入时,内镜超声引导下细针抽吸活检(EUS-FNA)可与内镜逆行胰胆管造影(ERCP)同期进行。
本研究旨在探讨 EUS-FNA 联合支架置入同期治疗胰腺癌的有效性。
连续纳入因胰腺肿块伴有胆道(±上消化道)梗阻症状而行 EUS-FNA 的患者。同期未行 EUS-FNA 但行胆道和/或十二指肠支架置入的患者作为对照组。主要观察指标为与操作相关的并发症。评估操作相关的并发症、操作时间、胆道/十二指肠支架置入的成功率、EUS-FNA 的取材量以及临床结局。
共 122 例患者接受了 EUS-FNA 联合支架置入,68 例患者仅接受了支架置入(对照组)。在联合组中,首次 EUS-FNA 时组织学证实癌症的比例为 88.52%,第二次 EUS-FNA 时为 95.08%。联合组和对照组的胆道支架置入成功率分别为 97.5%和 98%。两组内镜检查后住院时间、30 天内与操作相关的死亡率和发病率无统计学差异。联合组内镜检查至化疗的中位时间为 12 天。
对于疑诊胰腺癌的患者,几乎所有患者均可行 EUS-FNA 联合胆道和/或十二指肠支架置入,不会增加风险,且组织学取材量较高。